N.V. “announced interim clinical data as of a February 27, 2025 data cutoff from the ongoing phase 2 trial of the bispecific ...

Shares of Merus N.V. (MRUS) rocketed 32% on Friday morning after the stock witnessed price target hikes on the heels of the ...

PDS Biotechnology Corporation (NASDAQ:PDSB) unveiled compelling new data on its Versamune HPV (PDS0101) immunotherapy at the ...

Eligible patients with previously untreated, metastatic squamous non–small-cell lung cancer (NSCLC) were randomly assigned 1:1 to pembrolizumab 200 mg or placebo plus carboplatin and ...

Conference Call on Thursday, May 22 at 5:30 p.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), an ...

Despite a risk for severe side effects, pembrolizumab has a record of improving recurrence-free survival that makes it an ...

Poster presentation to highlight the ongoing global Phase 3 ASP-1929-381 study at ASCO 2025Global patient enrollment continues, with Taiwan now actively enrolling following the U.S., and Japan ...

Bicara Therapeutics (BCAX) stock plunges as the company reports data from a Phase 1/1b trial for its lead drug ficerafusp ...

Teos and GSK were the last to report a new setback in TIGIT targeting for non-small cell lung cancer patients. Read why I am ...

Shares of Merus jumped after the company posted positive interim data from a trial of its treatment for head and neck cancer. The stock rose 31% to $54.49 on Friday. Shares have climbed 24% over the ...

Five-year data from the KEYNOTE-048 trial support the use of pembrolizumab and pembrolizumab-chemotherapy as standards of care, researchers wrote.

Validation of lymphocyte to monocyte ratio in resected small bowel adenocarcinoma as a predictor of survival. This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting I. This abstract does ...